Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?Presenter:Noopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program:http://bit.ly/3rDeFCV 

There are no comments yet.

Please log in to write the first comment.